159 related articles for article (PubMed ID: 22950454)
21. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
22. Detection and characterization of an ABC transporter in Clostridium hathewayi.
Rafii F; Park M
Arch Microbiol; 2008 Oct; 190(4):417-26. PubMed ID: 18504552
[TBL] [Abstract][Full Text] [Related]
23. Molecular cloning and characterization of SmrA, a novel ABC multidrug efflux pump from Stenotrophomonas maltophilia.
Al-Hamad A; Upton M; Burnie J
J Antimicrob Chemother; 2009 Oct; 64(4):731-4. PubMed ID: 19643774
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of the PatAB Transporter Confers Fluoroquinolone Resistance to
Alvarado M; Martín-Galiano AJ; Ferrándiz MJ; Zaballos Á; de la Campa AG
Front Microbiol; 2017; 8():2074. PubMed ID: 29123510
[TBL] [Abstract][Full Text] [Related]
25. Role of PatAB Transporter in Efflux of Levofloxacin in
Amblar M; Zaballos Á; de la Campa AG
Antibiotics (Basel); 2022 Dec; 11(12):. PubMed ID: 36551495
[TBL] [Abstract][Full Text] [Related]
26. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the effect of bacterial efflux pumps on the antibacterial activity of the novel fluoroquinolone besifloxacin.
Shinabarger DL; Zurenko GE; Hesje CK; Sanfilippo CM; Morris TW; Haas W
J Chemother; 2011 Apr; 23(2):80-6. PubMed ID: 21571623
[TBL] [Abstract][Full Text] [Related]
28. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
29. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
[TBL] [Abstract][Full Text] [Related]
30. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Rozen DE; McGee L; Levin BR; Klugman KP
Antimicrob Agents Chemother; 2007 Feb; 51(2):412-6. PubMed ID: 17116668
[TBL] [Abstract][Full Text] [Related]
31. Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants.
Smith-Adam HJ; Nichol KA; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2005 Feb; 49(2):846-8. PubMed ID: 15673786
[TBL] [Abstract][Full Text] [Related]
32. Rapid screening of topoisomerase gene mutations by a novel melting curve analysis method for early warning of fluoroquinolone-resistant Streptococcus pneumoniae emergence.
Fukushima KY; Hirakata Y; Sugahara K; Yanagihara K; Kondo A; Kohno S; Kamihira S
J Clin Microbiol; 2006 Dec; 44(12):4553-8. PubMed ID: 17021062
[TBL] [Abstract][Full Text] [Related]
33. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005.
Ip M; Chau SS; Chi F; Cheuk ES; Ma H; Lai RW; Chan PK
Antimicrob Agents Chemother; 2007 Jun; 51(6):2192-4. PubMed ID: 17371818
[TBL] [Abstract][Full Text] [Related]
34. SatR is a repressor of fluoroquinolone efflux pump SatAB.
Escudero JA; San Millan A; Montero N; Gutierrez B; Ovejero CM; Carrilero L; González-Zorn B
Antimicrob Agents Chemother; 2013 Jul; 57(7):3430-3. PubMed ID: 23650171
[TBL] [Abstract][Full Text] [Related]
35. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
Iraurgui P; Torres MJ; Aznar J
Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
[TBL] [Abstract][Full Text] [Related]
36. Fluoroquinolone-resistant pneumococci: maybe resistance isn't futile?
Low DE
Clin Infect Dis; 2005 Jan; 40(2):236-8. PubMed ID: 15655740
[No Abstract] [Full Text] [Related]
37. Characterization of an ATP-binding cassette from Clostridium perfringens with homology to an ABC transporter from Clostridium hathewayi.
Rafii F; Park M; Carman RJ
Anaerobe; 2009 Aug; 15(4):116-21. PubMed ID: 19655423
[TBL] [Abstract][Full Text] [Related]
38. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.
Jumbe NL; Louie A; Miller MH; Liu W; Deziel MR; Tam VH; Bachhawat R; Drusano GL
Antimicrob Agents Chemother; 2006 Jan; 50(1):310-7. PubMed ID: 16377702
[TBL] [Abstract][Full Text] [Related]
39. Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.
Brenwald NP; Appelbaum P; Davies T; Gill MJ
Clin Microbiol Infect; 2003 Feb; 9(2):140-3. PubMed ID: 12588335
[TBL] [Abstract][Full Text] [Related]
40. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Fuller JD; Low DE
Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
